MedTrace Logo

Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression

NCT03977623 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-03-18

No results posted yet for this study

Summary

DLBCL has the highest frequency out of all lymphoid malignancies. With the recent development of antitumor agents targeting intracellular/extracellular cell signaling pathways, patients have access to various treatment options after relapse. Therefore, for the purpose of developing effective treatment strategies, large-scale genomic data accumulation is necessary to understand the mechanism of relapse and refractory state of DLBCL.

Conditions

  • Lymphoma, Large B-Cell, Diffuse

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-24
Primary Completion
2022-02-28
Completion
2022-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03977623 on ClinicalTrials.gov